 Home > Medical News > Latest Medical News > Bristol-Myers Squibb TYK2 inhibitor deucravacitinib enters review in the U.S. and Europe

Bristol-Myers Squibb TYK2 inhibitor deucravacitinib enters review in the U.S. and Europe

 Last Update: 2022-01-12
 Source: Internet
 Author: User

Tags

aleve anti inflammatory drug

buspirone drug

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Compilenewborn

On Monday, Bristol-Myers Squibb (BMS) announced that the U.

Deucravacitinib is the next-generation autoimmune drug of BMS.

But the problem is that TYK2 is a member of the JAK family, commonly known as JAK4

Samit Hirawat, chief medical officer of BMS, said in a recent interview that deucravacitinib has differentiated safety characteristics and does not have the downstream effects of JAK1/2/3, which is the target of existing JAK inhibitors

In order to win the U.

Data from 2 phase 3 clinical trials of plaque psoriasis announced earlier this year showed that BMS made the right choice

However, in October of this year, deucravacitinib also suffered a blow and failed in a phase 2 clinical trial for the treatment of ulcerative colitis (UC)

In addition to UC, BMS is also conducting another phase 2 clinical trial for the treatment of Crohn's disease (CD), which is another type of IBD

According to BMS estimates, all of these indications will be the basis for supporting deucravacitinib to reach a peak sales of $4 billion in 2029

BMS expects another asset with peak sales of more than $4 billion is the targeted heart drug mavacamten

Reference source: Bristol Myers Squibb's next-gen autoimmune med starts high-stakes FDA review amid classwide JAK scrutiny

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.